Download PDF
Klin Monbl Augenheilkd 2016; 233(04): 496-499
DOI: 10.1055/s-0041-111748
Der interessante Fall
Georg Thieme Verlag KG Stuttgart · New York

Ocular Manifestation of Non-Parenchymal Neuro-Behçet Syndrome

Okuläre Manifestation eines nonparenchymalen Neuro-Behçet-Syndromes
R. I. Bojinova
1   Department of Ophthalmology, University of Basel, Basel, Switzerland (Chairman ad interim: Prof. Selim Orgül)
2   Department of Medicine, McGill University, Montreal, Canada (Chairman: Dr. James Martin)
,
M. G. Todorova
1   Department of Ophthalmology, University of Basel, Basel, Switzerland (Chairman ad interim: Prof. Selim Orgül)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 April 2016 (online)

Also available at
    Permissions and Reprints

Background

Behçetʼs disease (BD) has been first described by Hippocrates, while it has been brought back to attention by Hulusi Behçet. Its classical triad includes recurrent, usually painful oral and genital ulcers and uveitis [1].

 

  • References

  • 1 Behçet H. Über rezidivierende, aphthose durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937; 105: 1152-1157
    PubMedGoogle Scholar
  • 2 Kokturk A. Clinical and pathological manifestations with differential diagnosis in Behçetʼs Disease. Patholog Res Int 2012; 2012: 690390
    PubMedGoogle Scholar
  • 3 Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76
    CrossrefPubMedGoogle Scholar
  • 4 Siva A, Saip S. The spectrum of nervous system involvement in Behçetʼs syndrome and its differential diagnosis. J Neurol 2009; 256: 513-529
    CrossrefPubMedGoogle Scholar
  • 5 Krist D, Schönherr U, Wenkel H. [Adamantiadis-Behçet syndrome: fluorescein angiography and choroid ischemia]. Klin Monbl Augenheilkd 2000; 216: 45-50
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Keino H, Okada AA, Watanabe T et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçetʼs disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245-1250
    CrossrefPubMedGoogle Scholar
  • 7 Hatemi G, Silman A, Bang D et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-1662
    CrossrefPubMedGoogle Scholar
  • 8 Fresko I, Yazici H. Treatment strategies for Behçetʼs disease. Expert Opin Pharmacother 2008; 9: 3211-3219
    CrossrefPubMedGoogle Scholar
  • 9 Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçetʼs disease: an update. Curr Opin Rheumatol 2011; 23: 24-31
    CrossrefPubMedGoogle Scholar
  • 10 Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012; 130: 592-598
    CrossrefPubMedGoogle Scholar